Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

How much is Novo Nordisk A/S ADR stock worth? Invest with precise valuations. Get Report.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Mostly clear. Winds northeasterly 25 to 40 km/h decreasing to 15 to 25 km/h in the late evening. Sun protection recommended from 9:10 am to 5:00 pm, UV Index predicted to reach 11 [Extreme] Partly ...